FierceBiotech names Gossamer Bio as one of its “Fierce 15” biotech companies of 2018

October 2, 2018

San Diego, CA – October 2, 2018 – Gossamer Bio, Inc. (“Gossamer Bio”) today announced that it has been named by FierceBiotech as one of 2018’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.

 

“We are honored to be selected as a Fierce 15 company for 2018,” said Sheila Gujrathi, M.D., Co-Founder and Chief Executive Officer of Gossamer Bio. “We have an exciting portfolio of innovative clinical and research stage programs across multiple indications that leverage our deep mechanistic understanding of immunobiology. With a focus on immunology, inflammation and immuno-oncology, our world-class team is committed to applying our collective expertise in discovery and development to bring forth important new medicines to patients who are suffering.”

 

The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition.  This is FierceBiotech’s 16th annual Fierce 15 selection.

 

An internationally recognized daily report reaching a network of over 285,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day’s top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

 

About Gossamer Bio
Gossamer Bio is a San Diego-based biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Our objective is to enhance and extend the lives of patients suffering from debilitating and life-threatening immunological diseases and cancer. We aim to create a business that allows value creation and capture at the individual asset level, long-term sustainability, and continuity. More information can be found at www.gossamerbio.com.

 

About FierceBiotech
FierceBiotech is the biotech industry’s daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 150,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day’s top stories. Signup is free at www.fiercebiotech.com/signup.

Share on Facebook
Share on Twitter
Please reload

Featured Posts

Vir's has two candidates that have proved highly potent in neutralising SARS-CoV-2 in live virus-cellular assays

GlaxoSmithKline PLC (LON:GSK) is to in...

GlaxoSmithKline injects US$250mln into US biotech Vir in coronavirus treatment collaboration

April 6, 2020

1/3
Please reload

Recent Posts
Please reload

Archive
Please reload